Adaptive Biotechnologies Corp vs Dollar Tree, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Dollar Tree, Inc. trades at $128.01 (market cap $24.61B). The key difference: Dollar Tree, Inc. is far larger — about 6.1× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | DLTR | |
|---|---|---|
Market Cap | $4.04B | $24.61B |
Sector | Health | Health |
52-Week High | $25.45 | $141.21 |
52-Week Low | $12.30 | $85.04 |
Enterprise Value | $4.10B | $31.20B |
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →